Literature DB >> 9129895

Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest.

F Gadler1, C Linde, A Juhlin-Dannfelt, A Ribeiro, L Rydén.   

Abstract

BACKGROUND: Atrioventricular-synchronous pacing is beneficial in patients with hypertrophic obstructive cardiomyopathy. The effects of pacing in patients without significant left ventricular outflow tract obstruction at rest are, however, less well explored. This study compares the long-term outcome of pacing patients with and without significant left ventricular outflow tract obstruction at rest.
METHODS: Forty-one patients with hypertrophic obstructive cardiomyopathy were studied, 19 with a left ventricular outflow tract gradient < 40 mmHg at rest, but exceeding 50 mmHg during provocation with isoproterenol (group A), and 22 with a left ventricular outflow tract obstruction > 40 mmHg at rest (group B). Before the implantation of a permanent pacemaker, the patients were studied according to a temporary pacing protocol. This included graded isoproterenol provocation of the left ventricular outflow tract obstruction, which was assessed by echo Doppler. Following permanent pacemaker implantation, the patients were regularly followed up with echo Doppler, exercise testing and monitoring of the clinical condition.
RESULTS: Isoproterenol provocation was reproducible and the technique did not cause any clinically important side effects. Left ventricular outflow tract gradient reduction after chronic pacing did not differ between the two groups. In group A, it decreased from 98 +/- 30 mmHg in sinus rhythm to 42 +/- 26 mmHg during pacing. The corresponding values in group B were 87 +/- 40 mmHg to 36 +/- 24 mmHg. The clinical condition improved similarly in the two groups. Exercise capacity increased significantly and perceived dyspnoea and angina pectoris were significantly lower at submaximal levels of exercise after 6 months of pacing.
CONCLUSION: Hypertrophic obstructive cardiomyopathy patients who only exhibit significant left ventricular outflow tract obstruction during provocation benefit as much from pacemaker treatment as do patients who already have significant obstruction at rest. Isoproterenol is a safe and reproducible method for pre-pacing evaluation of hypertrophic obstructive cardiomyopathy patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129895     DOI: 10.1093/oxfordjournals.eurheartj.a015309

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Beneficial effects of biventricular pacing in a patient with hypertrophic cardiomyopathy and intraventricular conduction delay.

Authors:  C A Rinaldi; C A Bucknall; J S Gill
Journal:  Heart       Date:  2002-06       Impact factor: 5.994

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  Dual-chamber pacing in hypertrophic cardiomyopathy.

Authors:  D M Gilligan
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

4.  Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients.

Authors:  Antonio Berruezo; Markus Linhart; Angelo Auricchio; José Luis Zamorano; Pilar Santamaria; Roger Borràs; Felip Burgos; Josep Brugada
Journal:  J Interv Card Electrophysiol       Date:  2018-02-03       Impact factor: 1.900

Review 5.  Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation.

Authors:  Robert M Cooper; Adeel Shahzad; Rodney H Stables
Journal:  Echo Res Pract       Date:  2014-10-30

6.  Right ventricular pacing for hypertrophic obstructive cardiomyopathy: meta-analysis and meta-regression of clinical trials.

Authors:  Ahran D Arnold; James P Howard; Kayla Chiew; William J Kerrigan; Felicity de Vere; Hannah T Johns; Leonid Churlilov; Yousif Ahmad; Daniel Keene; Matthew J Shun-Shin; Graham D Cole; Prapa Kanagaratnam; S M Afzal Sohaib; Amanda Varnava; Darrel P Francis; Zachary I Whinnett
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.